Velsera Partners with Illumina for Advanced Genomic Testing
In a significant advancement for precision medicine, Velsera has announced that its clinical Knowledgebase is powering the interpretation framework behind Illumina's TruSight™ Oncology Comprehensive (TSO Comp) assay. This assay has recently received regulatory approval, paving the way for enhanced genomic testing capabilities.
Understanding TruSight Oncology Comprehensive Assay
The TSO Comp assay is a next-generation sequencing (NGS)-based test designed for comprehensive genomic profiling of solid tumors. This innovative test is capable of detecting a broad spectrum of genomic alterations, including single nucleotide variants, insertions and deletions, copy number variations, and gene fusions, all from a single tumor sample.
The Role of Velsera's Knowledgebase
Velsera's Knowledgebase plays a crucial role in this testing procedure, linking detected variants to curated clinical evidence, treatment guidelines, and actionable insights. This integration ensures that healthcare professionals receive the most current and relevant data that can influence treatment decisions and patient outcomes.
Impact on Precision Oncology in Japan
The approval of TSO Comp in Japan is a remarkable step towards expanding access to standardized, evidence-based precision oncology. With this test now available commercially, clinicians are better equipped to make informed treatment decisions, ultimately enhancing the quality of care for cancer patients.
Commitment to Advancing Genomic Insights
Velsera's commitment to connecting healthcare professionals with actionable data underpins its mission to accelerate the delivery of genomics insights in clinical settings. As part of this initiative, Velsera’s clinical portfolio will be showcased at an upcoming significant event in the oncology community.
About Velsera
Founded in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec, Velsera has established itself as a leading platform for precision medicine. The company's mission is to empower experts in clinical diagnostics and life sciences to make informed decisions that ensure the right therapies reach the right patients at the right time. Operating in various regions including the United States, Europe, and Asia, Velsera is continually focused on enhancing clinical outcomes.
Contacts
For further inquiries, interested parties can reach out to Velsera directly. Brian Lassiter is available at 919-538-5611.
Frequently Asked Questions
What is the TSO Comp assay?
The TSO Comp assay is an NGS-based test that provides comprehensive genomic profiling of solid tumors, detecting various genomic alterations.
How does Velsera's Knowledgebase enhance the TSO Comp test?
It links detected variants to validated clinical evidence and guidelines, ensuring healthcare professionals receive up-to-date information for better decision-making.
What does the approval in Japan mean for patients?
This approval expands access to advanced genomic testing, supporting clinicians in making effective treatment decisions for cancer patients.
When was Velsera founded?
Velsera was founded in 2023 following the merger of three companies, enhancing its capacity in precision medicine.
What is the mission of Velsera?
Velsera aims to be a leading platform for discovery and clinical delivery in precision medicine, helping clinicians provide timely and appropriate therapies.
